China
Africa
Explore chapters and articles related to this topic
Pharmacology of the Lower Urinary Tract
Published in Karl H. Pang, Nadir I. Osman, James W.F. Catto, Christopher R. Chapple, Basic Urological Sciences, 2021
Pedro Abreu-Mendes, João Silva, Francisco Cruz
Adverse effects:~10% of men will report sexually related AEs:Erectile dysfunctionDecreased libidoDecreased volume of ejaculatePainful gynaecomastia (more common with dutasteride)
Mesotherapy: Dutasteride, Minoxidil, Vitamins
Published in Rubina Alves, Ramon Grimalt, Techniques in the Evaluation and Management of Hair Diseases, 2021
David Saceda, Claudia Bernárdez
There is no a standardized treatment regimen to perform mesotherapy with dutasteride (Table 12.6). First studies advocate repeating the procedure every 1 or 2 weeks, at least during the first 2 months. After that they recommend a monthly session. This intensive treatment could help to reach an adequate level of drug in the hair follicle. However, this hypothesis has never been proven. Further studies have suggested spaced procedures over time. Some authors defend monthly treatment or every 3 months. In our experience, performing the micro-injections of dutasteride every 3 months is more comfortable for the patient without losing efficacy.
What would make me an expert?
Published in Thomas A. Gerds, Michael W. Kattan, Medical Risk Prediction, 2021
Thomas A. Gerds, Michael W. Kattan
Consider the example of the drug Dutasteride for the prevention of prostate cancer [134]. This drug is controversial because it might lower the risk of prostate cancer in general yet raise the risk of an aggressive prostate cancer subtype. Moreover, the drug has some pleasant side effects as well as some undesirable side effects. Thus, there are tradeoffs with this drug, so it is important that a patient is fully informed of the advantages and disadvantages before taking the drug. But the risks of the good and bad outcomes depend on many things, such as the age of the patient, symptoms, blood test results, and other medical exams.
Effect of tadalafil on penile nitric oxide synthase and corporal smooth muscle in rats under dutasteride treatment
Published in The Aging Male, 2020
Abdullah Gul, Serdar Altinay, Levent Kabasakal, Abdulmecit Yavuz, Atilla Semercioz, Ege Can Serefoglu
Testosterone (T) turns into a more active compound dihydrotestosterone (DHT) by 5AR enzyme [6]. Two isoforms of this enzyme are present: type 1 and type 2 [7,8]. Dutasteride is one of the two 5ARI drugs used in the management of BPH-LUTS [7–9]. This agent inhibits both isoenzymes and decreases DHT concentrations in serum and prostatic tissue by 95% [10]. The initial research on the efficacy of dutasteride has reported sexual adverse events with a rate of 7.3% for erectile dysfunction (ED), 4.2% for reduced sexual desire, and 2.2% for ejaculatory dysfunction [11]. In another study, long-term dutasteride treatment resulted in decrease in International Index of Erectile Function (IIEF) scores and worsened ED [12]. However, the exact mechanism of these side effects has not been elucidated yet.
Gene expression of insulin receptor, insulin-like growth factor increases and insulin-like growth factor-binding protein-3 reduces with increase in prostate size in benign prostatic hyperplasia
Published in The Aging Male, 2018
Karli Sreenivasulu, Hanumanthappa Nandeesha, Lalgudi Narayanan Dorairajan, Medha Rajappa, Vickneshwaran Vinayagam, Cleetus Cherupanakkal
Benign prostatic hyperplasia (BPH) is the most common urological problem in aging men [1]. Although BPH is highly prevalent, the pathogenesis involved in the development of prostate growth remains uncertain. Among hormones, androgens play a prominent and essential role in normal and hyperplastic prostate growth [2]. Pradidarcheep has found an association between late onset hypogonadism and lower urinary tract symptoms (LUTS) indicating a link between low testosterone and symptoms suggestive of BPH [3]. Previous studies have found an improvement in PSA, prostate volume and LUTS after testosterone replacement therapy in patients with hypogonadism [4–7], where as Efesoy et al. and Meuleman et al. did not found any increase in prostate volume or PSA after treatment with testosterone [8,9]. Dutasteride, a 5-α reductase inhibitor used in the treatment of BPH was found to reduce PSA and prostate volume and it has been attributed to increase in testosterone levels [10].
Systematic review of mesotherapy: a novel avenue for the treatment of hair loss
Published in Journal of Dermatological Treatment, 2023
Aditya K. Gupta, Shruthi Polla Ravi, Tong Wang, Mesbah Talukder, Michela Starace, Bianca Maria Piraccini
Dutasteride is an inhibitor of the 5-α-reductase enzyme that inhibits the conversion of free testosterone to dihydrotestosterone, which is hypothesized to be the major contributor to AGA pathogenesis (12,13). When administered orally, a range of doses of dutasteride (0.05 − 2.5 mg daily) has been evaluated, with 0.5 mg daily being the most commonly reported and commercially available dosage (12). Using mesotherapy, the range of concentrations of dutasteride evaluated was 0.005 − 0.05%, administered at weekly, bi-monthly, or monthly intervals to treat PHL (Tables 1 and 2) (14–16). Mesotherapy reduces the frequency and dosage of administration, leading to the potential reduction of systemic off-target adverse effects (12).